RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-centre, Prospective, Placebo Controlled, Cohort Dose Escalation Study (RE-DEEM)

The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual antiplatelet treatment in patients with an index event (MI) at high risk for new ischaemic cardiovascular events.

本临床试验旨在评估，针对伴有首发事件（心肌梗死，Myocardial Infarction，缩写MI）且新发缺血性心血管事件风险较高的患者，在双联抗血小板治疗基础上加用每日两次口服达比加群酯（dabigatran etexilate，最多给药4剂）与安慰剂对照时的安全性与有效性指标。